Generic Name and Formulations:
Enalapril maleate, hydrochlorothiazide; 10mg/25mg; tabs.
Valeant Pharmaceuticals, Inc
Indications for VASERETIC:
Hypertension (not for initial therapy).
Switching from monotherapy with either component: start with Vaseretic 10/25 once daily, then adjust; max 20mg enalapril/day and 50mg HCTZ/day. Allow 2–3 weeks for titration of HCTZ component. Or, substitute for individually titrated components.
History of ACEI-associated or other angioedema. Anuria. Sulfonamide allergy. Concomitant neprilysin inhibitors (eg, sacubitril); do not administer lisinopril within 36hrs of switching to or from sacubitril/valsartan. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Severe renal impairment. Salt/volume depletion. Severe CHF. Ischemic disease. Cerebrovascular disease. Renal artery stenosis. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. SLE. Acute myopia. Secondary angle-closure glaucoma. Postsympathectomy. Monitor WBCs in renal or collagen vascular disease. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevations in hepatic enzymes develop. Monitor BP, electrolytes, and renal function. Black patients may have higher rate of angioedema than non-Black patients. Elderly. Neonates. Pregnancy, nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May cause hyperkalemia with K+-sparing diuretics, K+ supplements, or K+ -containing salt substitutes. Hypokalemia with corticosteroids, ACTH. May increase digitalis, lithium toxicity. Increased risk of angioedema with concomitant mTOR inhibitors (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. Potentiated by, and hypotension with diuretics, other antihypertensives. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Decreased absorption with cholestyramine, colestipol resins. May interfere with parathyroid tests.
ACE inhibitor + diuretic (thiazide).
Cough, dizziness, headache, fatigue, myalgia, nausea, asthenia, orthostatic hypotension, diarrhea, angioedema, fluid or electrolyte imbalance, impotence, hyperuricemia, renal impairment, arrhythmias, increased cholesterol and triglycerides; rare; hepatic failure.
Renal (primarily), fecal.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders